title: [Effect of conjugated estrogen and Org OD14 on serum lipoprotein and apolipoprotein in perimenopausal and postmenopausal women].
abstract: OBJECTIVE
  To determine the effect of conjugated estrogen and Org OD14 on serum lipoprotein and apolipoprotein in perimenopausal women.
  
  
  METHODS
  74 patients were divided into 2 groups: 46 were given conjugated estrogen 0.625 mg and medroxyprogesterone acetate 4 mg daily according to the continuous sequential, regimen 28 were given Org OD14 2.5 mg every two days. Serum lipoprotein and apolipoprotein estradiol and follicle stimulating hormone were measured before and (one and two years) after treatment.
  
  
  RESULTS
  Total Cholesterol (TC), Triglycerin (TG), high density lipoprotein (HDL-C), Apolipoprotein AI (Apo AI), Apolipoprotein AII (Apo AII), Apolipoprotein B(Apo B), Apolipoprotein CII(Apo CII), Apolipoprotein CIII(Apo CIII), Lipoprotein(a)[Lp(a)] increased significantly (P < 0.05), while ApoB/AI, ApoCII/CIII decreased significantly(P < 0.05) in conjugated estrogen group. ApoCIII, E decreased, while ApoAI/AII increased significantly (P < 0.05) in Org OD14 group. After two years treatment, TC, HDL-C, ApoAI, ApoCIII, ApoE, TC, HDL-C, ApoAI, ApoCIII, ApoE of conjugated estrogen group were higher than those of Org OD14 group(P < 0.05), ApoCII/CIII of Conjugated estrogen was lower than that of Org OD14 group(P < 0.05).
  
  
  CONCLUSIONS
  Postmenopausal hormone replacement therapy regulates the constitution of serum lipoprotein and apolipoprotein.
authors.affiliation: First Hospital of Beijing Medical University, Beijing 100034.
authors.forename: W
authors.initials: W
authors.lastname: Bai
authors.forename: X
authors.initials: X
authors.lastname: Yang
authors.forename: S
authors.initials: S
authors.lastname: Zheng
mesh_terms: D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood*; D001057:Apolipoproteins E / Q000097:blood; D002784:Cholesterol / Q000097:blood; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D008875:Middle Aged; D009652:Norpregnenes / Q000627:therapeutic use*; D017698:Postmenopause / Q000097:blood*; D017697:Premenopause / Q000097:blood*
chemical_list: D001053:Apolipoproteins; D001057:Apolipoproteins E; D004966:Estrogens, Conjugated (USP); D008075:Lipoproteins, HDL; D009652:Norpregnenes; D002784:Cholesterol; D017258:Medroxyprogesterone Acetate; C027385:tibolone